2027 ICD-10-CM Diagnosis Code C54.3Malignant neoplasm of fundus uteri

ICD-10-CM Codes›C00–D49›C51-C58›C54

ICD-10-CM C54.3
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

C54.3 is a billable ICD-10-CM diagnosis code for malignant neoplasm of fundus uteri. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 731 through 733, 754 through 756. Coders also document this condition as carcinoma of fundus of uterus. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Female reproductive system cancers - uterus.

For Medicare Advantage risk adjustment, C54.3 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
C54.3
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of fundus uteri
Short Description
Malignant neoplasm of fundus uteri
Same as the full description in the CMS dataset.
Parent Code
Malignant neoplasm of corpus uteri

Code Classification

ChapterC00–D49Neoplasms
SectionC51-C58Malignant neoplasms of female genital organs
CategoryC54Malignant neoplasm of corpus uteri
This CodeC54.3Malignant neoplasm of fundus uteri

Medicare Risk Adjustment (HCC)Billing

C54.3 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 23— Prostate, Breast, and Other Cancers and Tumors
Payment HCC · PY 2027 one of 234 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.186
community, non-dual, aged · ranges 0.186–0.237 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 12
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 12 · ESRD (V21): HCC 12 · ESRD (V24): HCC 12
ESRD V21 weights: 0.046 dialysis, 0.156–0.194 functioning graft · ESRD V24 weights: 0.045 dialysis, 0.162–0.219 functioning graft
Part D (RxHCC)
Not mapped
C54.3 does not risk-adjust in the RxHCC prescription drug model

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Carcinoma of fundus of uterus
  • Complex mixed and stromal malignant neoplasm of fundus uteri
  • Malignant neoplasm of fundus of corpus uteri
  • Neoplasm of fundus uteri
  • Primary malignant neoplasm of fundus uteri
  • Primary rhabdomyosarcoma of abdomen
  • Primary rhabdomyosarcoma of pelvis
  • Rhabdomyosarcoma of corpus uteri
  • Rhabdomyosarcoma of fundus uteri

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to C54.3: its own notes plus those printed at block C51-C58 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Includes

Further defines, or gives examples of, the content of the category.

From Block C51-C58 Malignant neoplasms of female genital organs applies to 36 codes
  • malignant neoplasm of skin of female genital organs

Notes

General instructions on how these codes are used.

From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name C54.3, its category, or a range that includes it.

Applicable To 2

These notes mention C54.3.

  • Z80.4 Family history of malignant neoplasm of genital organs
    Conditions classifiable to C51-C63 names C51-C63, which includes this code
  • Z85.4 Personal history of malignant neoplasm of genital organs
    Conditions classifiable to C51-C63 names C51-C63, which includes this code

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO031
Female reproductive system cancers - uterus
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
fundus › uterusC54.3C79.82D07.0D26.1D39.0D49.59
uterus, uteri, uterine › fundusC54.3C79.82D07.0D26.1D39.0D49.59

Patient EducationClinical

Uterine Cancer

Uterine cancer is a cancer that forms in tissues of the uterus, which is sometimes called the womb. The uterus is the place where a fetus grows during pregnancy.

The full article covers:

  • What is uterine cancer?
  • Who is more likely to develop uterine cancer?
  • What are the symptoms of uterine cancer?
  • How is uterine cancer diagnosed?
  • What are the treatments for uterine cancer?
  • Can uterine cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C54.3 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
182.0 Malig neo corpus uteri
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About C54.3Overview

What is the ICD-10 code for malignant neoplasm of fundus uteri?

The ICD-10-CM code for malignant neoplasm of fundus uteri is C54.3 (sometimes written as C543). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is C54.3 (Malignant neoplasm of corpus uteri) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of fundus uteri on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does C54.3 group to?

When malignant neoplasm of fundus uteri is the principal diagnosis on an inpatient stay, it groups to MS-DRG 732, 755, 756, 754, 733, 731, with relative weights from 0.8583 to 3.5462 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C54.3?

Under the General Equivalence Mappings, malignant neoplasm of fundus uteri converts to ICD-9-CM 182.0 (malig neo corpus uteri). The mapping is approximate, so confirm the match fits the documentation.

What HCC is C54.3?

C54.3 (malignant neoplasm of fundus uteri) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.

Does C54.3 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C54.3 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.